1 Personalized Medicine World Conference- Silicon Valley
Visit Q2 Solutions Booth #17, meet our Experts and attend our podium presentation to discover how genomics enhances clinical Immuno-oncology trials
About This Event
Attend our Podium Presentation during Genetics Informed Personalized Immunotherapy Session (Track 2) and Discover how Genomics Enhances Clinical Immuno-oncology Trials
Abstract: Immuno-oncology is developing at an unprecedented rate, with information integrated into drug development almost simultaneously. Accelerated bench-to-bedside practice brings great opportunity, but challenges emerge in the application of genomics to clinical trials. We will discuss test services developed by Q2 Solutions to enable translation of Immuno-oncology genomics in clinical trials.
Location: Computer History Museum
Speaker: Patrice Hugo, Ph.D., Chief Scientific Officer, Q2 Solutions
Date and Time: Tuesday, January 26, 2016 at 3:00 pm
We look forward to meeting you in Silicon Valley.
Immunology; Chief Scientific Officer
Dr. Patrice Hugo obtained his Ph.D. in Experimental Medicine/Immunology at McGill University and completed 5 years of post-doctoral fellowships in Immunology at the Walter Elisa Hall Institute in Australia, and at the Howard Hughes Medical Institute in Denver, Colorado. He then became a Principal Investigator leading the T-lymphocyte Unit at the Montreal Clinical Research Institute with academic appointments at McGill University and Montreal University. Throughout his academic work, Dr. Hugo focused on T-lymphocyte differentiation, self-tolerance induction, and leukemogenesis. He worked at PROCREA BioSciences and Caprion as Chief Scientific Officer and Executive Vice President R&D, respectively. Dr. Hugo was assigned as Chief Scientific Officer at Clearstone Central Laboratories later acquired by LabCorp and became Associate Vice President and Chief Scientist at LabCorp/Covance Central Laboratories Division. Dr. Patrice Hugo joined Q2 Solutions as Chief Scientific Officer where he currently leads the global scientific strategy and is responsible for the medical affairs and scientific activities of the Central Laboratories, and the Specialty Testing Centers of Excellence worldwide including Expression Analysis Genomics, Vaccine, Biomarkers and BioAnalytical/ADME laboratories. Dr. Hugo has more than 75 peer-reviewed scientific publications. He also played an active role in a number of industry organizations, including being a member of the Board of Directors for Personalized Medicine Partnership for Cancer in Quebec, and the Steering Committee for the Biomarker Factory. He is also a member of the American Society of Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC).